Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Neoadjuvant Therapy for Esophageal/GEJ Adenocarcinoma
NCT00938470Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2010
- Primary completion
- Dec 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, capecitabine in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, Gastric cardia adenocarcinoma (GCA), sponsored by Cancer and Leukemia Group B. Started Jan 2010; status: completed.
02
Drugs
docetaxelcapecitabine
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomaGastric cardia adenocarcinoma (GCA)
Beyond the preview
Go deeper on NCT00938470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00938470.